ASA Periopeative Pain Guidelines

The ASA has issued guidelines for acute pain management in the perioperative setting. Click on this link to read guidelines. Obviously there is a North American flavour to these guidelines, but they are generalisable.

Summary:

1. Institutional Policies and Procedures for Providing Perioperative Pain Management

  • Anaesthetists offering perioperative analgesia services should provide ongoing education and training to ensure that hospital personnel are knowledgeable and skilled with regard to the effective and safe use of the available treatment options within the institution.
  • Educational content should range from basic bedside pain assessment to sophisticated pain management techniques (e.g., epidural analgesia, PCA, and various regional anesthesia techniques) and non-pharmacologic techniques (e.g., relaxation, imagery, hypnotic methods – these are US guidelines!).
  • For optimal pain management, ongoing education and training are essential for new personnel, to maintain skills, and whenever therapeutic approaches are modified.
  • Anaesthetists and other healthcare providers should use standardized, validated instruments to facilitate the regular evaluation and documentation of pain intensity, the effects of pain therapy, and side effects caused by the therapy.
  • Anaesthetists responsible for perioperative analgesia should be available at all times to consult with ward nurses, surgeons, or other involved physicians.
  • They should assist in evaluating patients who are experiencing problems with any aspect of perioperative pain relief.
  • Anaesthetists providing perioperative analgesia services should do so within the framework of an Acute Pain Service.
  • They should participate in developing standardized institutional policies and procedures.

2. Preoperative Evaluation of the Patient

  • A directed pain history, a directed physical examination, and a pain control plan should be included in the anaesthetic preoperative evaluation.

3. Preoperative Preparation of the Patient

  • Patient preparation for perioperative pain management should include appropriate adjustments or continuation of medications to avert an abstinence syndrome, treatment of preexistent pain, or preoperative initiation of therapy for postoperative pain management.
  • Anaesthetists offering perioperative analgesia services should provide, in collaboration with others as appropriate, patient and family education regarding their important roles in achieving comfort, reporting pain, and in proper use of the recommended analgesic methods.
  • Common misconceptions that overestimate the risk of adverse effects and addiction should be dispelled.
  • Patient education for optimal use of PCA and other sophisticated methods, such as patient-controlled epidural analgesia, might include discussion of these analgesic methods at the time of the preanaesthetic evaluation, brochures and videotapes to educate patients about therapeutic options, and discussion at the bedside during postoperative visits.
  • Such education may also include instruction in behavioral modalities for control of pain and anxiety.

4. Perioperative Techniques for Pain Management

  • Anaesthetists who manage perioperative pain should use therapeutic options such as epidural or intrathecal opioids, systemic opioid PCA, and regional techniques after thoughtfully considering the risks and benefits for the individual patient.
  • These modalities should be used in preference to intramuscular opioids ordered “as needed.”
  • The therapy selected should reflect the individual anesthesiologist’s expertise, as well as the capacity for safe application of the modality in each practice setting.
  • This capacity includes the ability to recognize and treat adverse effects that emerge after initiation of therapy.
  • Special caution should be taken when continuous infusion modalities are used because drug accumulation may contribute to adverse events.

5. Multimodal Analgesia

  • Whenever possible, anaesthetists should use multimodal pain management therapy.
  • Unless contraindicated, patients should receive an around-the-clock regimen of NSAIDs or paracetamol.
  • Regional blockade with local anaesthetics should be considered.
  • Dosing regimens should be administered to optimize efficacy while minimizing the risk of adverse events.
  • The choice of medication, dose, route, and duration of therapy should be individualized.

6. Patient Subpopulations

Paediatric patients

  • Aggressive and proactive pain management is necessary to overcome the historic under-treatment of pain in children.
  • Perioperative care for children undergoing painful procedures or surgery requires developmentally appropriate pain assessment and therapy.
  • Analgesic therapy should depend upon age, weight, and comorbidity, and unless contraindicated should involve a multimodal approach.
  • Behavioral techniques, especially important in addressing the emotional component of pain, should be applied whenever feasible.
  • Sedative, analgesic, and local anaesthetics are all important components of appropriate analgesic regimens for painful procedures.
  • Because many analgesic medications are synergistic with sedating agents, it is imperative that appropriate monitoring be used during the procedure and recovery.

Geriatric patients

  • Pain assessment and therapy should be integrated into the perioperative care of geriatric patients.
  • Pain assessment tools appropriate to a patient’s cognitive abilities should be used. Extensive and proactive evaluation and questioning may be necessary to overcome barriers that hinder communication regarding unrelieved pain.
  • Anaesthetists should recognize that geriatric patients may respond differently than younger patients to pain and analgesic medications, often because of comorbidity.
  • Vigilant dose titration is necessary to ensure adequate treatment while avoiding adverse effects such as somnolence in this vulnerable group, who are often taking other medications (including alternative and complementary agents).

Other subpopulations

  • Anaesthetists should recognize that patients who are critically ill, cognitively impaired, or have communication difficulties may require additional interventions to ensure optimal perioperative pain.management.
  • Anaesthetists should consider a therapeutic trial of an analgesic in patients with increased blood pressure and heart rate or agitated behavior when causes other than pain have been excluded.

Local Anaesthesia Toxicity (tutorial)

Patrick Neligan, Consultant in Anaesthesia & Intensive Care, Galway University Hospitals (c)

Clinical Scenario

A 37 year old female undergoes bilateral mammoplasty. The procedure is performed under general anaesthesia. Prior to incision the wound was infiltrated with 20ml of 1% lignocaine, on each side. Intraoperatively the patient’s temperature was 37.5 degrees celcius, heart rate was 100 to 120 beats/min and blood pressure was 100/50. Prior to extubation, the surgeon injects 5ml of lignocaine 1% subcutaneously into each breast.

Neuromuscular blockade is reversed with neostigmine and glycopyrrolate and the patient returned to the recovery on supplemental oxygen.

Following admission to recovery, the patient complains of dizziness, shortness of breath and paraesthesia around the mouth and tongue. Her temperature is 38 degrees celcius, heart rate 106, blood pressure 90/50, respiratory rate 30. She says that she has a choking feeling. Moments later she loses consciousness and has a grand mal seizure.

What is the likely mechanism of injury?

Local anaesthetics are drugs that produce reversible depression of signal conduction along nerve fibers. Depending on the dose and site of application, they cause analgesia, anaesthesia and neuromuscular blockade.

The first local anaesthetic discovered was cocaine. Subsequent synthesis of alternative agents early in the twentieth century were ester derivatives of benzoic acid. These are known as “ester” local anaesthetics. Lignocaine was synthesized in 1943 – an amide derivative of diethylamino acetic acid (“amides”). Most subsequent agents introduced into practice have been amides due to lower associated incidence of side effects (principally anaphylaxis).

Local anaesthetics work by blocking voltage gated sodium channels. They interrupt the influx of sodium into nerve cells, preventing propagation of the action potential.

The agent, a weak base, is injected as hydrochloride salt in an acid solution – tertiary amine group becomes quaternary and suitable for injection (i.e. dissolves in solution). Following injection, the pH increases (due to the higher pH of the tissues, which is usually 7.4) and the drug dissociates, the degree of which depends on pKa, and free base is released. Lipid soluble (because it is uncharged) free base enters the axon. Inside the axon the pH is lower (because the environment is more acidic), and re-ionization takes place (to BH+). The re-ionized portion enters the Na+ channels and blocks them, preventing depolarization.

Figure 1: Mechanism of Action of Local Anaesthetic Agents

Although local anaesthetics are administered to be injected locally there is always associated systemic absorption. Adrenaline is commonly added to the local anaesthetic mixture to induce local vasoconstriction and reduce the absorbed dose. However, if sufficiently large amounts of drug are absorbed, either due to excessive administration or due to inadvertent intravascular injection, complications may ensue. Conversely, lignocaine has been used for decades as an intravenous therapeutic agent in the management of cardiac arrhythmias, and reduction in the adrenergic response to surgical incision.

Local anaesthetics exert toxic effects on the cardiovascular and central nervous system. This became apparent in the late 1970s and early 1980s when a series of patients developed profound cardiovascular depression, in some cases fatal, associated with administration of bupivicaine in high dosage. Bupivicaine, particularly its S-enantiomer, binds irreversibly (covalently) to cardiac conduction tissue – blocking sodium, potassium and calcium channels.

Prior to the development of cardiovascular symptoms and signs, the patient will manifest signs of neurologic toxicity (figure 2). At low levels of toxicity the patient may complain of circumoral numbness, higheadeness and ringing in the ears. These symptoms should alert the clinician to stop the administration of local anaesthetic infusions, through implanted catheters such as epidurals. Increasing toxicity leads to visual disturbances, muscle twitching and convulsions (as in this case). Continued toxicity leads to loss of consciousness, coma, respiratory and cardiac arrest.

Symptoms and signs of CNS toxicity are thought to commence with selective blockade of fast sodium channels in the central nervous system and inhibition of gama-aminobutyric acid (GABA) in cortical cerebral inhibitory pathways. Excitatory neurons appear to be more resistant to local anaesthetics. Consequently, at moderate levels of toxicity (figure 2) there is unopposed activity of these excitatory neurons leading to seizures. With progressive toxicity, there is generalized CNS depression. The occurrence of seizures, then, is an important warning sign of imminent catastrophe.

Local anaesthetics agents, in particular lignocaine, have been used as anti-arrhythmic agents. They produce dose dependent depression of cardiac conduction, by blocking sodium channels. This principally affects sino-atrial and atrio-ventricular nodal conduction. Consequently, the PR interval and duration of the QRS complex is prolonged. Further, as all electrical activity in the heart and vascular smooth muscle is depressed, local anaesthetics have a negative impact on myocardial contractility and cause peripheral vasodilatation. Thus there is a dose dependent fall in cardiac output and blood pressure with inability to compensate. Increasing levels of toxicity may cause severe bradycardia, cardiogenic shock and cardiovascular collapse.

 

What is this cc/cns ratio?

The cardiovascular system is significantly more resistant to the toxic effects of local anaesthetics. Indeed, with moderate CNS toxicity, the increase in excitatory activity may lead to tachycardia and increased cardiac output. However, the onset of convusions is an ominous clinical sign and it is important to anticipate the risk of a devastating cardiovascular event. The cc/cns ratio is the ratio of dosage or blood levels required to produce irreversible cardiovascular collapse to that level required to produce convulsions. The lower the ratio, the more potentially hazardous the drug is. The cardiovascular to CNS ratio for bupivicaine is 2.0, for lignocaine it is 7.1, for ropivicaine it is 2.2. Hence, of the commonly used perioperative local anaesthetic agents, bupivicaine and ropivicaine are potentially significantly more toxic than lignocaine. Thus the appearance of seizures in the patient in question is less of a concern in that she received lignocaine, not bupivicaine. It is believed that the mechanism behind the greater cardiovascular toxicity of bupivicaine is that it much more slowly dissociates from cardiac conduction tissue than lignocaine. This prolongs the refractory period, and reduces conductivity through regular pathways. This significantly increases the risk for malignant ventricular arrhythmias.

Toxicity

Note that by “toxicity” I mean neurologic depression as a direct extension of the pharmacologic effects of the drug. Certain additional factors are likely to increase the risk of neurologic toxicity, these include respiratory (increased PaCO2) and metabolic acidosis, leading to reduced protein binding, or the administration of benzodiazepines or barbiturates.

Toxicity depends on the amount of free drug in plasma; this relates to three factors:

1. Dose given.

2. Rate of injection (the effective dose given).

3. Site of injection (the greater the blood supply to the area injected the greater the systemic absorption). Sites of absorption from greatest to least:

interpleural > intercostal > pudendal > caudal > epidural > brachial plexus > infiltration

(in this scenario the patient received drug principally by infiltration),

TREATMENT

Treatment for CNS toxicity of local anaesthetics is essentially supportive (figure 3). Ensure that the airway is patent and that the patient is breathing spontaneously. Apply supplemental oxygen. Lay the patient flat. Ensure that the patient has iv access and that intravenous fluid is running. Check the patient’s pulse and blood pressure. If the patient is unconscious, a jaw thrust may be required to prevent airway obstruction. Do not place any devices between the patient’s teeth if they are seizing. If necessary place a nasopharyngeal airway.

If the seizure does not rapidly self-resolve, then intravenous midazolam (0.05 to 0.1mg/kg), lorazepam (0.1mg/kg) or diazepam (5 – 10mg) may be administered to control seizure activity. If this fails, phenobarbitone or thiopentone may be administered intravenously. An alternative approach would be to secure the airway following induction of anaesthesia with propofol and administration of a propofol infusion. Hypoxia should be treated aggressively as should acidosis: respiratory acidosis is managed by increasing alveolar ventilation. Metabolic acidosis is resolved with restoration of oxygen flow, intravenous fluids and, in extreme cases, administration of sodium bicarbonate. The treatment for LA induced arrhythmia is Bretylium 7mg/kg. Phenytoin should not be used for seizures, because it is also a sodium channel blocker.

Intravenous intralipid® (20%) appears to be effective at minimizing adverse cardiovascular outcomes. There are many case reports and animal studies that have demonstrated rapid resolution of cardiovascular symptoms associated with this lipid emulsion. Intralipid is the major component of total parenteral nutrition. It is believed that the lipid acts as a bank for local anaesthetic – the drug has more affinity for the lipid than for cardiac tissue; as the amount of buipivicaine bound up to cardiac tissue is reduced, normal contractile function results. There are no randomized controlled trials supporting its use, and it is unlikely that there ever will be (similar to dantrolene for malignant hyperthermia). Although propofol contains lipid, the concentration is insufficient to have a beneficial effect. Intralipid is inexpensive and has a long shelf life; consequently there is no reason why it cannot be stored in any location in which anaesthesia is delivered.

The Association of Anaesthetists in Great Britain and Ireland (aagbi.org) have issued guidelines for the use of intralipid in the event of LA toxicity: initial bolus of 100ml 1.5ml/kg over 1 minute) followed by 400ml (0.25 ml/kg) over 20 mins. Repeat boluses can be administered subsequently: 100ml at 5 minute intervals repeated x2 and then 400ml administered over 10 minutes.  CPR should be continued until the circulation has been re-established. If all of this fails – cardiopulmonary bypass may be instituted until the local anaesthetic has been metabolized.

 

Figure 2: Treatment of Local Anaesthesia Toxicity

Click here for the AAGBI A4 sheet.   Click here for the accompanying notes.

CONCLUSIONS

  • Local anesthetic toxicity can be seen with local anesthetic wound infiltration, epidural catheter placement, and nerve blocks.
  • Signs of low level CNS toxicity from local anesthetics include: circumoral numbness, lightheadedness, and tinnitus.
  • Increasingly higher concentrations of local anesthetic toxicity leads to visual disturbances, seizures, loss of consciousness, respiratory and cardiac arrest.
  • The greater the blood supply at the site of local anesthetic injection, the greater systemic absorption of the drug.
  • The maximum safe doses of local anesthetics are: bupivicaine 2 mg/kg (2.5mg/kg with adrenaline), lignocaine 5mg/kg (7mg/kg with adrenaline), levobupivicaine (chirocaine) 2-3mg/kg, ropivicaine (naropin) 3-4mg/kg, prilocaine 6 mg/kg.
  • There are various causes of post-op seizures, including intracranial bleeding following craniotomy, stroke, hypoglycemia, electrolyte imbalance, hypoxia, and drug or local anesthetic toxicity.
  • Treatment for CNS toxicity caused by local anesthetics is supportive, including maintaining a patent airway, monitoring vital signs, administering IV fluids, and giving antiseizure medications.
  • Intralipid is currently recommended to prevent the development of cardiovascular toxicity associated with LA toxicity. The mechanism of action is unknown.

DRUG

LIGNOCAINE

PRILOCAINE

BUPIVACAINE

LEVOBUPIVACAINE

ROPIVACAINE

Relative potency

2

2

8

8

6

Onset

5-10 min

5-10 min

10-15 min

10-15 min

10-15 mins

Duration
without adrenaline

1-2 hours

1-2 hours

3-12 hours

3-12 hours

3-12 hours

Duration
with adrenaline

2-4 hours

2-4 hours

4-12 hours

4-12 hours

4-12 hours

Max dose
without adrenaline

3 mg/kg

6 mg/kg

2 mg/kg

2.5 mg/kg

3 mg / kg

Max dose
with adrenaline

7 mg/kg

9 mg/kg

2.5 mg/kg

3 mg/kg

4 mg / kg